Product Overview

Contimira S 25 is a combination therapy formulated with Mirabegron Extended Release 25 mg and Solifenacin Succinate IP 5 mg for the effective management of Overactive Bladder (OAB). By combining a β3-adrenoceptor agonist with an antimuscarinic agent, the formulation provides a comprehensive therapeutic approach to reducing urinary urgency, increased urinary frequency, and urge urinary incontinence.

Designed to improve bladder function and patient comfort, Contimira S 25 offers dual-action therapy that helps patients achieve better symptom control than monotherapy in appropriate clinical settings. The extended-release formulation of Mirabegron provides sustained therapeutic activity while Solifenacin helps reduce involuntary bladder contractions, supporting improved urinary control throughout the day.

How It Works

Contimira S 25 combines two complementary mechanisms of action. Mirabegron activates β3-adrenergic receptors in the bladder, promoting relaxation of the bladder muscle during the storage phase and increasing bladder capacity. Solifenacin Succinate blocks muscarinic receptors responsible for involuntary bladder contractions, reducing symptoms such as urinary urgency, frequency, and urge incontinence. Together, these actions provide enhanced symptom relief and improved bladder control.

Therapeutic Applications

Contimira S 25 may be prescribed for the management of:

• Overactive Bladder (OAB)
• Urinary Urgency
• Increased Urinary Frequency
• Urge Urinary Incontinence
• Mixed Overactive Bladder Symptoms
• Patients requiring combination therapy as determined by the treating physician

Key Benefits

• Dual-action therapy for comprehensive Overactive Bladder management.
• Helps reduce urinary urgency and frequency.
• Supports improved bladder capacity and urinary control.
• Extended-release formulation for sustained therapeutic effect.
• May improve quality of life in patients with Overactive Bladder.
• Manufactured under stringent pharmaceutical quality standards.

Quality Commitment

Vinix Biopharma is committed to delivering high-quality urology products that meet stringent pharmaceutical manufacturing standards. Contimira S 25 is manufactured under controlled production environments and undergoes rigorous quality assurance procedures to ensure safety, consistency, and reliability. Every batch is carefully tested to maintain product integrity and support effective patient care.

Storage Information

Store in a cool, dry place below 30°C. Protect from moisture and direct sunlight. Keep out of reach of children.

Disclaimer

Contimira S 25 should be used only under the supervision of a qualified healthcare professional. The dosage and duration of therapy should be determined by the treating physician based on the patient’s clinical condition and therapeutic requirements.